Global Glaucoma Therapeutics Market is estimated to be 12

1. Global Glaucoma Therapeutics Market is estimated to be 12.0 billion by 2029 with a CAGR of 6.2% during the forecasted period. The global glaucoma therapeutics market accounted for 7.0 billion in 2020 and is estimated to be US$ 12.0 billion by 2029 and is anticipated to register a CAGR of 6.2%. The report "Global Glaucoma Therapeutics Market, By Drug Class (Alpha adrenergic Agonist, Beta Blockers, Prostaglandin Analogs, Carbonic Anhydrase Inhibitor, Cholinergic, Combined Medication, and Fixed-dose Combinations), By Disease Type (Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”. Key Market Insights from the report: The global glaucoma therapeutics market accounted for 7.0 billion in 2020 and is estimated to be US$ 12.0 billion by 2029 and is anticipated to register a CAGR of 6.2%. The market report has been segmented on the basis of drug class, disease type, distribution channel and region. Depending upon drug class, the prostaglandin analogs segment is projected to grow at highest CAGR over the forecast period owing to its efficacy to reduce intraocular pressure (IOP) and other side effect as compared to other therapies. Depending disease type, the primary open angle glaucoma (POAG) segment is projected to grow at highest CAGR over the forecast period. This is attributed to the high prevalence of disorder, as compare to other type of glaucoma. Additionally the majority type of drug present in the market for POAG which will consider driving the market growth. Depending distribution channel, the hospital pharmacy segment is projected to grow at highest CAGR over the forecast period. However, the highest growth is estimated to record by the retail pharmacy segments. An increasing preference of treatments in outpatient settings among the elderly population is anticipated to drive the growth of targeted market. By region, North America holds dominant position in glaucoma therapeutics market, followed by Asia Pacific. Increasing prevalence of diabetes, increasing ocular disorders, and increasing number of blind and visually impaired people in turn opting for glaucoma treatment are expected to drive growth of the glaucoma therapeutic market in this region. To know the upcoming trends and insights prevalent in this market, click the link below: https://www.prophecymarketinsights.com/market_insight/Global-Glaucoma-Therapeutics- Market-4495 Competitive Landscape: The prominent player operating in the global glaucoma therapeutics market includes Valeant Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd., Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote

2. financial growth. Furthermore, the report exhibits dynamic factors including segments, sub- segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report. Key Highlights: In December 2019, Senju Pharmaceutical Co., Ltd. announced the launched of its product AIBETA, a combination of drug to manage glaucoma and hypertension in Japan. In May 2020, AbbVie Inc. completed the strategic acquisition of Allergan plc. This acquisition has enabled AbbVie Inc. to establish itself as a leader in the glaucoma market. Analyst View: Increasing number of diabetic patients and geriatric population Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is related to abnormal vessel growth, which may end in retinopathy and results in blockage of natural drainage of the attention. Rapidly increasing geriatric population is one among the important factors for the increasing prevalence of glaucoma, which successively is projected to drive the expansion of the glaucoma therapeutics market in near future. For instance, per the International Diabetes Foundation (IDF) 2017 statistics, the number of individuals with diabetes aged between 20 to 79 years is increasing worldwide. Among which, Africa (156%) is accounted to register the highest diabetic population, followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%), North America (35%), Europe (16%), and Western Pacific (15%). Rising prevalence of glaucoma The increasing prevalence of glaucoma among the geriatric population is one of the major factors to drive the market growth. The increasing use of screen gadgets like laptops and smart phones are the main cause for rising incidence of glaucoma. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG. Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “GlobalGlaucoma TherapeuticsMarket”, By Drug Class (Alpha adrenergic Agonist, Beta Blockers, Prostaglandin Analogs, Carbonic Anhydrase Inhibitor, Cholinergic, Combined Medication, and Fixed-dose Combinations), By Disease Type (Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029 About Prophecy Market Insights Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

3. Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period Key Topics Covered 1.Introduction Study Deliverables Study Assumptions Scope of the Study 2.Research Methodology 3.Executive Summary Opportunity Map Analysis Market at Glance Market Share (%) and BPS Analysis, by Region Competitive Landscape Heat Map Analysis Market Presence and Specificity Analysis 4.Investment Analysis 5.Competitive Analysis To know more Contact Us: Sales Prophecy Market Insights Email- sales@prophecymarketinsights.com